Laboratory Testing Prior to Initiating Korlym (Mifepristone) or Recorlev (Relacorilant)
Before starting either Korlym or Recorlev, you must obtain a negative pregnancy test in all females of reproductive potential, along with baseline complete blood count (CBC), comprehensive metabolic panel (CMP) including liver function tests (LFTs), and potassium levels.
Mandatory Pre-Treatment Testing
Pregnancy Testing (Critical - FDA Requirement)
- Obtain negative pregnancy test within 48 hours prior to initiating treatment 1
- Required for all females of reproductive potential
- Must be repeated if treatment is interrupted for more than 14 days
- This is non-negotiable due to mifepristone's potent antiprogestational effects that will terminate pregnancy 1
Baseline Laboratory Panel
Based on the FDA label for Korlym and general principles for monitoring cortisol receptor antagonists 1, obtain:
Essential baseline labs:
- Complete blood count (CBC) with differential - to establish baseline hematologic parameters
- Comprehensive metabolic panel (CMP) including:
- Liver function tests (ALT, AST, alkaline phosphatase, bilirubin)
- Renal function (BUN, creatinine)
- Serum potassium - critical as both drugs can cause hypokalemia through increased mineralocorticoid activity 2, 1
- Glucose/HbA1c - to establish baseline glycemic control (particularly relevant for Cushing's syndrome patients)
Additional recommended testing:
- Thyroid function tests (TSH, free T4) - Cushing's syndrome patients may have thyroid abnormalities
- Morning cortisol and ACTH - to document baseline hypercortisolism (though note that cortisol levels cannot be used for monitoring during mifepristone treatment) 2, 3
Key Monitoring Considerations
Why These Labs Matter
Potassium monitoring is particularly important because mifepristone's glucocorticoid receptor antagonism can unmask mineralocorticoid effects, leading to hypokalemia, hypertension, and edema 2, 1. This is a recognized adverse effect that requires vigilant monitoring.
Liver function testing establishes a baseline before treatment, as hepatotoxicity can occur with various medications used in Cushing's syndrome management 2. While not specifically highlighted as a major concern with mifepristone in the FDA label, baseline LFTs are standard practice.
Special Populations
Renal impairment: No change in initial dosing required, but document baseline renal function 1
Hepatic impairment: Baseline LFTs are essential; severe hepatic impairment is a contraindication to Korlym use 1
Contraception Counseling (Mandatory)
Along with laboratory testing, you must:
- Counsel patients on non-hormonal contraception (mifepristone reduces effectiveness of hormonal contraceptives) 1
- Document contraceptive plan or surgical sterilization status
- Continue contraception for one month after stopping treatment
Common Pitfall to Avoid
Do not rely on cortisol levels for monitoring treatment response with mifepristone - the drug blocks cortisol receptors but doesn't lower cortisol levels, so UFC and serum cortisol remain elevated or increase during treatment 2, 3. Clinical parameters (glucose control, blood pressure, weight, symptoms) must guide dose adjustments instead.
The evidence base for relacorilant (Recorlev) is more limited as it received recent approval 4, but similar monitoring principles apply given its mechanism as a selective GR-II antagonist. Follow the same baseline testing protocol, with particular attention to pregnancy testing, potassium, and metabolic parameters.